Clinical Trial Results:
Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance
Summary
|
|
EudraCT number |
2017-002707-10 |
Trial protocol |
DK |
Global end of trial date |
16 Feb 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Oct 2024
|
First version publication date |
09 Oct 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SJ-596
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04117178 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Department of Neurology ZUH
|
||
Sponsor organisation address |
Vestermarksvej 4000, Roskilde, Denmark,
|
||
Public contact |
RVD, Regional Dementia Research Centre, Dept of Neurology, 0045 47322800, phh@regionsjaelland.dk
|
||
Scientific contact |
RVD, Regional Dementia Research Centre, Dept of Neurology, 0045 47322800, suh-neu@regionsjaelland.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
02 Sep 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
16 Feb 2023
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
16 Feb 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate whether serum-monitoring of anti-dementia drugs may reduce side-effects and improve clinical efficacy and patient compliance.
NOTA BENE: two fictonal (male 'in utero') study participants (from Åland Islands) have been added to this report because the webside does not allow for validation without this ridiculous amendment.
|
||
Protection of trial subjects |
the trial was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Both the regional scientific ethics committee (Videnskabsetisk komité for Region Sjælland, file no.: SJ-596) and the Danish Medicines Agency approved the trial . The trial protocol was approved by the local data supervisory authority (Datatilsynet Region Sjælland, approval no.: REG-007-2018). The Good Clinical Practice (GCP) unit of Copenhagen monitored the study externally and conducted regular site inspections.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
12 Feb 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 132
|
||
Country: Number of subjects enrolled |
Åland Islands: 2
|
||
Worldwide total number of subjects |
134
|
||
EEA total number of subjects |
132
|
||
Number of subjects enrolled per age group |
|||
In utero |
2
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
16
|
||
From 65 to 84 years |
105
|
||
85 years and over |
11
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
A total of 132 participants were enrolled from February 12th, 2020, to February 24th, 2022. Of the 132 participants, 25 were registered as drop-outs either due to participant decision to withdraw or if treatment was changed to an anti-dementia drug not investigated in the trial (galanmantine, rivastigmine). | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
Patients attending the study site for patient visits were screened according to the inlcusion and exclusion criteria. Elegibile patients were offered trial participation during the visit where the diagnosis and treatment options were presented. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Single-blinded RCT (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Single blind | ||||||||||||||||||||||||||||||
Roles blinded |
Assessor [1] | ||||||||||||||||||||||||||||||
Blinding implementation details |
Assessor of clinical end points blinded to group allocation of participants. Also, the statistical analysis was done in a blinded manner.
|
||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Control group | ||||||||||||||||||||||||||||||
Arm description |
Standard of care | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Standard care
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
participants had their treatment titrated according to the standard of care at the study site. Hence, participants scheduled for donepezil were prescribed 5 mg./d for 4 weeks and then if well-tolerated the dose was increased to 10 mg./d. Participants scheduled for memantine were initially prescribed 5 mg./d, with a gradual dose-increase of 5 mg. the following weeks to a maximum of 20 mg./d.
|
||||||||||||||||||||||||||||||
Arm title
|
Intervention group | ||||||||||||||||||||||||||||||
Arm description |
Dosing of donepezil or memantine based on therapeutic drug monitoring | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
TDM based dosing
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
For the IG, the PI adjusted treatment at the 6 months visit according to the serum concentration of the study drug in addition to relevant clinical information identical to that of the CG. We presumed that the lower limit of the TRR for serum donepezil (S-donepezil) was 50ng/mL. Accordingly, for participants in the IG, if the 10 mg/d dosage was well-tolerated and the serum concentration was below the 50ng/mL threshold we increased to daily dose to 15 or 20 mg/d. We applied the same procedure for treatment with memantine, with the lower limit set at serum memantine (S-memantine) 90 ng/mL. The maximum allowed daily dose in the study was 20 mg/d and 30 mg/d for donepezil and memantine respectively.
|
||||||||||||||||||||||||||||||
Notes [1] - The roles blinded appear inconsistent with a simple blinded trial. Justification: The assessor of clinical endpoints was blinded to group allocation |
|||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Control group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Standard of care | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intervention group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Dosing of donepezil or memantine based on therapeutic drug monitoring | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Control group
|
||
Reporting group description |
Standard of care | ||
Reporting group title |
Intervention group
|
||
Reporting group description |
Dosing of donepezil or memantine based on therapeutic drug monitoring |
|
|||||||||||||
End point title |
Mean change on Addenbrooke's Cognitive Exam from baseline to 12-month follow-up | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline to 12-month follow-up
|
||||||||||||
|
|||||||||||||
Notes [1] - Due to dropout the number of subjects at 12 month was 49 [2] - Due to withdrawal 58 subjects were assessed at 12 months |
|||||||||||||
Statistical analysis title |
Linear regression models with GEE | ||||||||||||
Statistical analysis description |
We assessed the clinical outcomes at 12 months follow-up in linear regression models. Clinical outcomes were assessed using linear regression models comparing the difference between the baseline effect (difference in outcome between the randomization arms at study start) and the 12-month follow-up effect (difference in outcome between the randomization arms at the 12-month follow-up). We used generalized estimating equations (GEE) to accommodate for repeated measurements on the same study partic
|
||||||||||||
Comparison groups |
Control group v Intervention group
|
||||||||||||
Number of subjects included in analysis |
107
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Change on MMSE [3] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline to 12 month follow-up
|
||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: It was presumed that at least 50% of serum concentrations would be out of the recommended range without TDM based dose optimization and that the use of TDM based dose optimization would result in at least 75% of participants reaching a serum concentration within the TRR. Hence 55 participants were needed in each group with a significance level of 5% and a power of 80% in a Z-test for absolute difference in proportions. |
|||||||||||||
|
|||||||||||||
Notes [4] - Due to dropout the number of subjects at 12 months was 49 [5] - Due to dropout the number of subjects at 12 months was 58 |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change on Geriatric Depression Scale | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline to 12 month follow-up
|
||||||||||||
|
|||||||||||||
Notes [6] - Due to dropout the number of subjects at 12 months was 49 [7] - Due to dropout the number of subjects at 12 months was 58 |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change on Neuropsychiatric Inventory | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline to 12 month follow-up
|
||||||||||||
|
|||||||||||||
Notes [8] - Due to dropout the number of subjects at 12 months was 49 [9] - Due to dropout the number of subjects at 12 months was 58 |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change on Disability Assessment in Dementia | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline to 12 month follow-up
|
||||||||||||
|
|||||||||||||
Notes [10] - Due to dropout the number of subjects at 12 months was 49 [11] - Due to dropout the number of subjects at 12 months was 49 |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change on Clinical Global Impression Scale Improvement | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline to 12 month follow-up
|
||||||||||||
|
|||||||||||||
Notes [12] - Due to dropout the number of subjects at 12 months was 49 [13] - Due to dropout the number of subjects at 12 months was 58 |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From baseline to 12 month follow-up
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
medicine prod. info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intervention group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants in intervention group | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Control group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
This study did not support general usage of TDM based dose optimization for donepezil and memantine in dementia, albeit important study limitations and caveats to the external validity of the results apply. |